Physician profile
Eric V Ngo
NPI 1942658059
$5,383.26
in general payments reported to CMS, 2019-2025
33 companies · $1,574 in 2025
The $1,574 reported for 2025 was more than what 77% of Pain Medicine (Anesthesiology) providers received nationally (typical 2025 total: $458).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $252 · 2022: $783 · 2023: $877 · 2024: $1,897 · 2025: $1,574.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,012 · Travel and Lodging: $336.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,012.05 |
| Travel and Lodging | $335.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,633.86 | 2022-2025 | Intellis Adaptivestim, Inceptiv, V-Loc 180 |
| Ucb, INC. | $655.83 | 2024-2025 | Briviact, Rystiggo, Fintepla |
| Boston Scientific Corporation | $374.77 | 2021-2024 | Wavewriter Alpha Prime 16, Infinion 16, Superion Indirect Decompression System |
| Takeda Pharmaceuticals U.S.A., INC. | $278.68 | 2024-2025 | Hyqvia |
| Abbvie INC. | $273.80 | 2022-2025 | |
| Amgen INC. | $225.60 | 2024 | Uplizna |
| Nevro Corp. | $219.60 | 2021-2024 | Senza |
| Eisai INC. | $202.00 | 2024-2025 | |
| Lilly USA, LLC | $167.53 | 2024-2025 | Amyvid, Kisunla, Emgality |
| Astrazeneca Pharmaceuticals LP | $167.07 | 2024 | Andexxa |
| Alexion Pharmaceuticals, INC. | $142.99 | 2024-2025 | Ultomiris |
| Novartis Pharmaceuticals Corporation | $133.77 | 2024-2025 | |
| Abbott Laboratories | $116.60 | 2023-2025 | Proclaim, Eterna |
| Argenx US, INC. | $102.97 | 2024-2025 | Vyvgart Hytrulo |
| Tonix Medicines, INC. | $84.05 | 2025 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Spr Therapeutics, INC | $74.71 | 2022-2025 | Sprint Pns System |
| Teva Pharmaceuticals USA, INC. | $71.20 | 2024-2025 | Austedo Xr, Austedo Xr |
| Collegium Pharmaceutical, INC. | $60.52 | 2024-2025 | Xtampza |
| Impel Pharmaceuticals LLC | $45.70 | 2025 | Trudhesa |
| Sk Life Science, INC. | $45.38 | 2024 | |
| Biotronik Nro, INC. | $36.50 | 2024-2025 | Prospera |
| Biogen, INC. | $35.73 | 2025 | Vumerity, Tysabri, Avonex |
| Averitas Pharma INC. | $34.61 | 2024-2025 | Qutenza |
| Neurocrine Biosciences, INC. | $31.96 | 2024 | Ingrezza |
| Acadia Pharmaceuticals INC | $23.59 | 2025 | Nuplazid |
| Sumitomo Pharma America, INC. | $22.95 | 2024 | Gemtesa |
| Genzyme Corporation | $20.22 | 2025 | |
| Vertex Pharmaceuticals Incorporated | $19.05 | 2025 | |
| Tersera Therapeutics LLC | $19.05 | 2025 | Prialt |
| Pacira Pharmaceuticals Incorporated | $18.25 | 2023 | Iovera |
| Emd Serono, INC. | $16.50 | 2024 | |
| Vanda Pharmaceuticals INC. | $14.53 | 2025 | Ponvory |
| Genentech USA, INC. | $13.69 | 2025 | Ocrevus Zunovo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Ngo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.